Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Immutep Limited is an Australian clinical-stage biotechnology company developing immunotherapy treatments for cancer and autoimmune diseases, centered around its proprietary LAG-3 (Lymphocyte Activation Gene-3) platform technology. The company's lead asset, eftilagimod alpha (efti), is in Phase IIb/III trials for first-line metastatic breast cancer and head/neck cancer, with multiple partnership agreements including Merck KGaA and Merck & Co. As a pre-revenue biotech, the stock is driven entirely by clinical trial readouts, regulatory milestones, partnership deals, and cash runway management.
Immutep operates a classic clinical-stage biotech model: it develops proprietary LAG-3 immunotherapy assets through Phase I/II trials, then partners with larger pharmaceutical companies (Merck KGaA, Merck & Co., Novartis) who provide upfront payments, fund later-stage development, and pay milestone payments upon achieving clinical/regulatory endpoints. The company retains royalty rights (typically mid-single to low-double digit percentages) on future commercial sales. With negative gross margins reflecting R&D-heavy operations and no product revenue, the business model depends on: (1) demonstrating clinical proof-of-concept to trigger milestone payments, (2) maintaining sufficient cash runway through equity raises or partnerships, and (3) ultimately achieving regulatory approval for royalty streams. The LAG-3 mechanism offers differentiation from PD-1/PD-L1 checkpoint inhibitors, potentially commanding premium partnership terms.
Phase IIb/III clinical trial data readouts for eftilagimod alpha in metastatic breast cancer (TACTI-003 trial) and head/neck cancer - positive efficacy data can drive 50-100%+ moves
Partnership expansion announcements or milestone payment triggers from existing deals with Merck KGaA, Merck & Co., or new pharma collaborations
Regulatory milestone achievements: IND filings, Fast Track designations, Breakthrough Therapy designations, or BLA/NDA submissions
Cash position updates and equity financing announcements - dilutive raises typically pressure stock 10-30%, while non-dilutive partnerships provide support
Competitive LAG-3 data from Bristol-Myers Squibb (relatlimab) or other immuno-oncology competitors affecting platform validation
Clinical trial failure risk: Phase IIb/III trials have ~40-50% historical failure rates in oncology; negative efti data would eliminate primary value driver and likely require strategic restructuring
Regulatory pathway uncertainty: FDA/EMA standards for immuno-oncology combination therapies continue evolving; potential for additional trial requirements or restricted label approvals
Competitive obsolescence: Rapid advancement in CAR-T, bispecific antibodies, and next-generation checkpoint inhibitors could render LAG-3 mechanism less differentiated before commercialization
Reimbursement pressure: Even with approval, payers increasingly scrutinize high-cost oncology therapies; combination regimens face particular pricing challenges versus monotherapies
Bristol-Myers Squibb's relatlimab (approved LAG-3 antibody) establishes competitive benchmark; superior efficacy or safety required for efti differentiation in crowded checkpoint inhibitor market
Large pharma internal LAG-3 programs: Merck, Roche, and others developing competing LAG-3 assets with greater resource bases and established commercial infrastructure
Partnership dependency: Reliance on Merck KGaA and Merck & Co. for development funding and commercialization creates strategic vulnerability if partners deprioritize programs
Cash runway constraints: Current $0.4B market cap with -$0.1B annual cash burn implies need for financing within 18-24 months absent partnership milestones; dilutive equity raises likely
Equity financing overhang: Pre-revenue biotechs typically require multiple financing rounds; 38.9% 3-month return suggests recent capital raise or positive catalyst, but future dilution risk remains material
Partnership milestone concentration: Revenue dependent on achieving specific clinical endpoints; binary milestone structure creates lumpy cash flow and potential liquidity stress if trials delayed
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. Trial timelines, patient enrollment, and regulatory processes proceed independently of economic cycles. However, partnership activity and M&A valuations can soften during recessions as big pharma becomes more conservative with capital allocation. Patient access to clinical trials may be marginally affected by healthcare utilization patterns during severe downturns.
Rising interest rates create significant valuation pressure on pre-revenue biotechs through two mechanisms: (1) higher discount rates compress NPV of distant cash flows (potential royalties 5-10 years out), disproportionately affecting long-duration assets, and (2) risk-off sentiment shifts capital away from speculative growth stocks toward safer yield alternatives. The company's minimal debt (0.01 D/E) means direct financing cost impact is negligible, but equity financing becomes more expensive/dilutive in high-rate environments. Historical biotech indices show 30-40% correlation with 10-year Treasury movements.
Minimal direct credit exposure. The company does not extend credit to customers (no product sales) and maintains highly liquid balance sheet (11.69x current ratio). Indirect exposure exists through pharmaceutical partner creditworthiness for milestone payments, but partnerships are with investment-grade entities (Merck KGaA, Merck & Co.). Broader credit market tightening can reduce biotech M&A activity and partnership deal flow, potentially extending time to monetization events.
growth/speculative - Attracts high-risk-tolerance investors seeking asymmetric returns from clinical-stage biotech binary events. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders playing catalyst-driven volatility. Not suitable for value or income investors given negative cash flows and no dividends. The 25% 1-year return with 38.9% 3-month spike suggests momentum/event-driven interest around recent clinical updates or partnership news.
high - Clinical-stage biotechs exhibit extreme volatility around binary catalysts (trial readouts, FDA decisions). Expect 30-50% intraday moves on material news. Low float and institutional concentration amplify price swings. Implied volatility typically 60-80%+ ahead of data readouts. Beta likely 1.5-2.0x versus biotech indices, higher versus broad market.